MESOBLAST LTD- SPON ADR (MESO) Stock Overview
NASDAQ:MESO - US5907174016 - ADR
MESO Key Statistics, Chart & Performance
The current stock price of MESO is 13.83 USD. In the past month the price decreased by -8.83%. In the past year, price increased by 105.19%.
MESO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About MESO
Company Profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 73 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.
Company Info
MESOBLAST LTD- SPON ADR
L 38 55 Collins St
Melbourne VICTORIA 3000 AU
CEO: Silviu Itescu
Employees: 73
Phone: 61396396036
MESOBLAST LTD- SPON ADR / MESO FAQ
What is the stock price of MESOBLAST LTD- SPON ADR today?
The current stock price of MESO is 13.83 USD. The price decreased by -13.29% in the last trading session.
What is the ticker symbol for MESOBLAST LTD- SPON ADR stock?
The exchange symbol of MESOBLAST LTD- SPON ADR is MESO and it is listed on the Nasdaq exchange.
On which exchange is MESO stock listed?
MESO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MESOBLAST LTD- SPON ADR stock?
9 analysts have analysed MESO and the average price target is 15.77 USD. This implies a price increase of 14.04% is expected in the next year compared to the current price of 13.83. Check the MESOBLAST LTD- SPON ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MESOBLAST LTD- SPON ADR worth?
MESOBLAST LTD- SPON ADR (MESO) has a market capitalization of 1.76B USD. This makes MESO a Small Cap stock.
How many employees does MESOBLAST LTD- SPON ADR have?
MESOBLAST LTD- SPON ADR (MESO) currently has 73 employees.
What are the support and resistance levels for MESOBLAST LTD- SPON ADR (MESO) stock?
MESOBLAST LTD- SPON ADR (MESO) has a support level at 13.82 and a resistance level at 13.84. Check the full technical report for a detailed analysis of MESO support and resistance levels.
Is MESOBLAST LTD- SPON ADR (MESO) expected to grow?
The Revenue of MESOBLAST LTD- SPON ADR (MESO) is expected to grow by 170.93% in the next year. Check the estimates tab for more information on the MESO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MESOBLAST LTD- SPON ADR (MESO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MESO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MESO, evaluating the profitability, health, valuation and growth aspects
- MESOBLAST LTD- SPON ADR (MESO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MESOBLAST LTD- SPON ADR (MESO) Sales and EPS estimates to see what analysts future expectations are.
- MESOBLAST LTD- SPON ADR (MESO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MESOBLAST LTD- SPON ADR (MESO) Insider and Institutional Ownership to learn about the owners and their transactions.
- MESOBLAST LTD- SPON ADR (MESO) Stock Chart to make your own analysis
- MESOBLAST LTD- SPON ADR (MESO) Latest news and press-releases to stay up to date.
Does MESOBLAST LTD- SPON ADR (MESO) stock pay dividends?
MESO does not pay a dividend.
When does MESOBLAST LTD- SPON ADR (MESO) report earnings?
MESOBLAST LTD- SPON ADR (MESO) will report earnings on 2025-08-29, after the market close.
What is the Price/Earnings (PE) ratio of MESOBLAST LTD- SPON ADR (MESO)?
MESOBLAST LTD- SPON ADR (MESO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.8).
What is the Short Interest ratio of MESOBLAST LTD- SPON ADR (MESO) stock?
The outstanding short interest for MESOBLAST LTD- SPON ADR (MESO) is 2.59% of its float. Check the ownership tab for more information on the MESO short interest.
MESO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MESO. When comparing the yearly performance of all stocks, MESO is one of the better performing stocks in the market, outperforming 94.49% of all stocks.
MESO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MESO. MESO may be in some trouble as it scores bad on both profitability and health.
MESO Financial Highlights
Over the last trailing twelve months MESO reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 15.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.46% | ||
| ROE | -19.07% | ||
| Debt/Equity | 0.23 |
MESO Forecast & Estimates
9 analysts have analysed MESO and the average price target is 15.77 USD. This implies a price increase of 14.04% is expected in the next year compared to the current price of 13.83.
For the next year, analysts expect an EPS growth of 17.29% and a revenue growth 170.93% for MESO